Welcome to our dedicated page for Bruker news (Ticker: BRKR), a resource for investors and traders seeking the latest updates and insights on Bruker stock.
Bruker Corporation (Nasdaq: BRKR) regularly issues news and updates on its activities in scientific instruments, diagnostics, superconducting technologies, and advanced research collaborations. This news page aggregates company press releases and third-party coverage so readers can review developments affecting Bruker’s analytical instruments, diagnostic solutions, and related businesses.
Recent announcements highlight multi-year orders in the Bruker Energy & Supercon Technologies (BEST) division for high-performance superconductors used in MRI magnets, including materials that support helium-free MRI magnet architectures. News items also cover orders for high-field NMR and EPR systems from leading European research institutions for materials science, battery research, and disease biology, illustrating how Bruker’s magnetic resonance systems are deployed in academic and government research environments.
Bruker’s news flow also reflects its expansion in applied mass spectrometry and diagnostics. The company has reported the consolidation of full ownership of TOFWERK AG, adding ultra-fast time-of-flight mass spectrometry for real-time air and semiconductor cleanroom monitoring, atmospheric chemistry research, exposomics, and food, flavors and fragrances testing. It has also been associated with the acquisition of AST Revolution, an in vitro diagnostics company focused on rapid antimicrobial susceptibility testing (AST) solutions built around the WAVE and Arc systems.
Investors and researchers following BRKR news can expect updates on earnings releases and financial guidance, capital structure developments such as preferred stock offerings and dividends, board and governance changes, and strategic transactions. This page is a convenient entry point for tracking how Bruker’s instruments, diagnostics, and superconducting technologies are being adopted across life sciences, applied markets, industrial and cleantech research, and semiconductor-related applications.
Bruker has announced a strategic partnership with Biognosys, acquiring a majority stake to enhance access to Biognosys' CRO services and Spectronaut® software for proteomics research. The partnership aims to support drug discovery, biomarker development, and clinical trials, with plans to establish a new advanced proteomics facility in the US. The collaboration leverages Bruker's technology alongside Biognosys' expertise, promising improved proteomics capabilities and expanded services for their biomarker and biopharma clientele.
Bruker Corporation (Nasdaq: BRKR) will present at the 41st annual J.P. Morgan Healthcare Conference on January 9, 2023, at 10:30 AM EST in San Francisco. Key executives, including Chairman Frank Laukien and CFO Gerald Herman, will represent the company. A live audio webcast of the presentation can be accessed via the Investor Relations section of Bruker's website, with a replay available for 30 days thereafter. Bruker specializes in high-performance scientific instruments that support significant advancements in life sciences and material sciences.
Bruker Corporation (Nasdaq: BRKR) announced significant multi-year contracts valued at approximately $50 million with its majority-owned RI Research Instruments GmbH and Bruker Energy & Supercon Technologies (BEST). These contracts involve supplying key technology components for major fusion projects in Europe and Asia. The projects include providing Inner Vertical Targets for the ITER fusion initiative and high-current density RRP® superconductors for a tokamak project. This advancement positions Bruker to play a vital role in future sustainable energy solutions.
Kiyatec Inc. has successfully closed its Series C funding round, raising US$18 million led by new investor Bruker (BRKR) and supported by LabCorp (LH) and others. The funds will enhance the adoption of Kiyatec's clinical testing and preclinical pharma services, vital for improving cancer treatment outcomes. Kiyatec's 3D-Predict™ Glioma test has shown significant clinical correlations, allowing better therapy selection for glioblastoma patients. The company aims to grow its revenue through innovative testing and drug development partnerships.
Bruker Corporation (Nasdaq: BRKR) has signed a definitive agreement to acquire Neurescence Inc., known for its innovative Multiscopes™ technology that allows simultaneous multi-region optical neuroimaging. Neurescence's Chromatone™ system, which minimizes weight on animals, enhances the investigation of neuron functions. This acquisition strengthens Bruker's portfolio in animal imaging and expands its capabilities in neuroresearch. Financial terms of the deal were not disclosed, but the acquisition is expected to leverage synergies with Bruker's existing products, positioning the company as a leader in this field.
Bruker Corporation (NASDAQ: BRKR) has announced a quarterly cash dividend of
Bruker Corporation (Nasdaq: BRKR) announced its acquisition of Inscopix, a leader in miniaturized microscopes for neuroscience research. Inscopix's innovative equipment has been deployed in 600+ institutions globally, facilitating advances in understanding neurological disorders. This acquisition is expected to enhance Bruker's in-vivo imaging capabilities, combining high-resolution multiphoton microscopy with Inscopix’s advanced miniaturized technology. Inscopix's projected FY 2022 revenue is $20-25 million, with expectations of continued double-digit growth.
Bruker Corporation (Nasdaq: BRKR) will participate in the 2022 Jefferies London Healthcare Conference on November 15, 2022, at 12:00 PM Eastern Time.
Bruker specializes in high-performance scientific instruments and analytical solutions, enabling breakthroughs in life sciences and diagnostics.
Bruker Corporation (Nasdaq: BRKR) reported Q3 2022 revenue of $638.9 million, a 4.9% increase year-over-year, with organic growth at 12.7%. GAAP EPS rose to $0.59, and non-GAAP EPS increased 4.8% to $0.66. The company raised its FY 2022 guidance for organic revenue growth to 8%-10%, up from 7%-9%, while non-GAAP operating margin guidance was also increased to 60-90 bps. Additionally, Bruker's backlog and high-demand products contributed to a strong financial outlook despite currency translation headwinds of 8%.
Bruker Corporation (Nasdaq: BRKR) will release its Q3 2022 financial results on November 3, 2022, before market opening. A conference call will follow at 8:30 a.m. ET to discuss the results and business trends. Investors can participate via webcast or telephone, with an option to pre-register for expedited entry. A replay of the call will be available until December 3, 2022. Bruker focuses on providing high-performance scientific instruments and solutions, enhancing research in life sciences and diagnostics.
FAQ
What is the current stock price of Bruker (BRKR)?
What is the market cap of Bruker (BRKR)?
